| Title |
Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, December 2011
|
| DOI | 10.1007/s00228-011-1180-7 |
| Pubmed ID | |
| Authors |
Michael W. Jann, Vicky Spratlin, Kathryn Momary, Hailing Zhang, David Turner, Scott R. Penzak, Alan Wright, Chad VanDenBerg |
| Abstract |
To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Portugal | 1 | 3% |
| Unknown | 29 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 26% |
| Student > Master | 5 | 16% |
| Student > Ph. D. Student | 5 | 16% |
| Student > Bachelor | 2 | 6% |
| Librarian | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 8 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 35% |
| Business, Management and Accounting | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 9 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2011.
All research outputs
#20,152,153
of 22,659,164 outputs
Outputs from European Journal of Clinical Pharmacology
#2,376
of 2,548 outputs
Outputs of similar age
#219,139
of 241,496 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#25
of 30 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,548 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,496 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.